Tag: Moxetumomab pasudotox-tdfk
FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia treatment
Lumoxiti FDA approval : AstraZeneca has bagged the US Food and Drug Administration (FDA) approval for its CD22-directed cytotoxin Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment ... Read More